Cyclophosphamide drug data and news

---

Brussels shares close lower; Dexia, KBC losses weigh UPDATE  Mar 2, 2006
Cimzia is a very important product for UCB as it forms the cornerstone of its strategy to minimize the impact of the patent expiry of Zyrtec in December 2007 ... - Forbes

HOME PAGE FOR THE WORLD'S BUSINESS LEADERS  Mar 2, 2006
...first time. Next year it is the turn of Pfizer’s blood pressure drug, Norvasc, and allergy pill Zyrtec, also from Pfizer. The ... - Forbes

UPDATE 1-UCB files Cimzia drug for US approval in Crohn's  Mar 2, 2006
Cimzia represents a key asset for UCB, which faces loss of US patent protection on its top-selling allergy drug Zyrtec in December 2007. ... - Reuters

Pfizer forecasts higher profit from new drugs  Feb 10, 2006
The company faces the loss of exclusivity for many of its key products -- Diflucan, Zithromax, Zoloft, Norvasc and Zyrtec -- over the next several years, but ... - Crain's New York Business,

Flat now, Pfizer looking to acquisitions, new drugs  Feb 12, 2006
Many of its top-selling drugs are on the verge of losing sales to generics, with the anti-depressant Zoloft, the allergy pill Zyrtec and the blood pressure ... - Chicago Tribune,

UPDATE 1-Reuters Summit-UCB commits to R&D, bullish on Cimzia  Feb 22, 2006
...in around a year's time and it represents a key asset for UCB, which faces loss of US patent protection on its top-selling allergy drug Zyrtec in December 2007 ... - Reuters

FDA approves generic Flonase spray  Feb 24, 2006
The patent on Flonase, which the FDA approved in 1994, expired in May 2004. The patent on the antihistamine Zyrtec expires in 2007. ... - Fort Worth Star Telegram,

Business briefs  Feb 24, 2006
MARLBORO — UCB SA, the Belgian maker of the allergy drug Zyrtec, bought the US rights to another allergy treatment, Sepracor Inc.’s levocetirizine, taking ... - Worcester Telegram (subscription),

If syrup is sullied, how do we conquer a cough?  Feb 21, 2006
The newer, nondrowsy antihistamines do not help a cough, the chest doctors say. These include Allegra, Claritin and Zyrtec. — Drink ... - Canton Repository (subscription),

UCB Receives EMEA Positive Opinion and FDA Approvable Letter for ...  Feb 3, 2006
UCB key products are Keppra® (levetiracetam), Zyrtec®† (cetirizine HCl), Tussionex® CIII (hydrocodone polistirex/chlorpheniramine polistirex), and ... - PharmaLive.com (press release),

Pfizer sees '06 profit slightly under the weather  Feb 10, 2006
In 2007, Pfizer stands to lose its patent on Norvasc, the blood pressure treatment with $4.7 billion in 2005 sales, and on Zyrtec, an allergy treatment with ... - CNN International

Pfizer's Listerine Unit May Attract Novartis, J&J (Update2)  Feb 8, 2006
The company is cutting $4 billion from annual costs by 2008 as patents expire on five products in the next five years, including the Zyrtec allergy medicine ... - Bloomberg

Four questions for Pfizer  Feb 7, 2006
...in 2005 sales. Also in 2007, Pfizer faces patent loss on Zyrtec, an allergy treatment with $1.3 billion in 2005 sales. When a branded ... - CNN/Money

Pfizer is working against the clock  Feb 19, 2006
...billion in sales. Patent expires in 2007. Zyrtec: An allergy treatment with $1.3 billion in sales. Patent expires in 2007. Lipitor: A ... - DetNews.com,

With the Need to Focus on Rx Pipeline, Pfizer Mulls Divestiture of ...  Feb 13, 2006
Faced with the impending patent expirations for some of its key prescription medications, including Zyrtec, Zoloft, and Norvasc, as well as challenges to ... - PharmaLive.com (press release),

UCB Sale Less Important Than Zyrtec Results  Jan 17, 2006
...sale of its bioproducts manufacturing division to Switzerland's Lonza (LONN.VX) is less important than the upcoming results for its star drug, Zyrtec, says KBC ... - New Ratings

UCB Zyrtec Results Lower-Than-Expected  Jan 20, 2006
0857 GMT [Dow Jones] UCB (UCB.BT) results for key Zyrtec and Xyzal antihistimine drugs are "lower-than-expected," says KCB, but not enough to influence ... - New Ratings

UCB's Zyrtec US Sales Below Expectation  Jan 19, 2006
1453 GMT [Dow Jones] Sales of UCB's (UCB.BT) Zyrtec drug in 4Q came in a touch lower than expected at $3.27M, says KBC's Christophe Van Vaeck, who had expected ... - New Ratings

UCB confirms good 2005 performance of Zyrtec in US and Xyzal  Jan 19, 2006
Brussels, Belgium - January 19, 2005 - Following Pfizer's quarterly earnings release, UCB confirms that Zyrtec continues to strengthen its leadership position ... - Market Wire (press release)

Pfizer's Listerine Unit May Attract Novartis, J&J, Analysts Say  Feb 7, 2006
The company is cutting $4 billion from annual costs by 2008 as patents expire on five products in the next five years, including the Zyrtec allergy medicine ... - Bloomberg

Four questions for Pfizer  Feb 7, 2006
...in 2005 sales. Also in 2007, Pfizer faces patent loss on Zyrtec, an allergy treatment with $1.3 billion in 2005 sales. When a branded ... - CNN/Money

UCB Receives EMEA Positive Opinion and FDA Approvable Letter for ...  Feb 3, 2006
UCB key products are Keppra® (levetiracetam), Zyrtec®† (cetirizine HCl), Tussionex® CIII (hydrocodone polistirex/chlorpheniramine polistirex), and ... - PharmaLive.com (press release),

An open letter to the pharmaceutical industry  Jan 29, 2006
It sure would be nice to not have to spend time figuring out if a particular patient's insurance covers Claritin, Clarinex, Zyrtec or Allegra for their ... - Staunton News Leader,

Loris councilman guilty of drug charges  Jan 13, 2006
...to four charges of distributing the illegal drug hydrocone, two charges of distributing marijuana, possession of oxycodone and possession of Zyrtec without a ... - Myrtle Beach Sun News,

Pfizer Fourth-Quarter and Full-Year 2005 Financial Results Reflect ...  Jan 19, 2006
...market acceptance of Lyrica, and better-than-anticipated performance in certain key markets (Japan and Germany) and in certain key products (Zyrtec and Norvasc ... - PR Newswire (press release),

Got a cough? Over-the-counter syrup has little value, physicians ...  Jan 10, 2006
Allergy. Newer, expensive antihistamines do not help a cough, the group said. This includes Allegra, Claritin and Zyrtec. Some doctors ... - Newsday,

MARKET COMMENT: Brussels Stocks Seen Opening 0.4% Higher  Jan 19, 2006
Traders also watch Pfizer '05 results, which affect UCB since the US drug company distributes its star drug Zyrtec, expected to be released around 1130 GMT. ... - New Ratings

HealthCheck Chat Transcript  Jan 18, 2006
...the allergist. Does she have allergies? If so they need to be addressed - possible with more than just Zyrtec. Chronic hives may ... - 6abc.com,

Merck, Wyeth Sales Rise Little as Top Drugs Slow (Update1)  Jan 31, 2006
...face the loss of patent protection this year and next including the Zoloft antidepressant, the blood-pressure medicine Norvasc and the Zyrtec allergy medicine. ... - Bloomberg

So, if syrup is sullied, how do we conquer a cough?  Jan 31, 2006
The newer, non-drowsy antihistamines do not help a cough, the chest doctors say. These include Allegra, Claritin and Zyrtec. Drink ... - San Diego Union Tribune,

No evidence cough syrups work, panel says  Jan 25, 2006
...chlorpheniramine, he said. Newer, brand-name antihistamines such as Claritin and Zyrtec do not help coughs, Dicpinigaitis said. Under new ... - Daily Nation (subscription),

Inhaled insulin for diabetics wins FDA's OK  Jan 28, 2006
Investors are bracing for generic drugs to battle with Pfizer's Zoloft, an antidepressant; Norvasc, a blood pressure treatment; and Zyrtec, an allergy remedy. ... - Boston Globe,

Pfizer Fourth-Quarter Net Falls 3 Percent; Lipitor Sales Slow  Jan 19, 2006
...patent protection. Next year, Pfizer patents expire for the Norvasc blood-pressure treatment and the Zyrtec allergy medicine. The ... - Bloomberg

HUGIN NEWS/Lonza Acquires the Bioproducts Manufacturing Division ...  Jan 16, 2006
UCB key products are Keppra® (antiepileptic), Xyzal® and Zyrtec® (antiallergics), Nootropil® (cerebral function regulator), Tussionex® (antitussive) and ... - Frankfurter Allgemeine Zeitung,

Brussels shares close up; Umicore recoups losses after sell-off ...  Jan 19, 2006
The company announced earlier in the session that US sales of its antihistamine drug Zyrtec rose 6 pct year-on-year to 1.362 bln usd in 2005, while worldwide ... - Forbes

Chest doctors discourage use of over-the-counter cough syrup  Jan 9, 2006
This includes drugs such as Benadryl and Dristan. Newer, expensive antihistamines such as Allegra, Claritin and Zyrtec do not help, the group said. ... - Austin American-Statesman (subscription),

Cough syrups get the cold shoulder from doctors group  Jan 10, 2006
Allergy. Newer, more expensive antihistamines do not help a cough, the group said. Those includes Allegra, Claritin and Zyrtec. Over ... - Columbus Dispatch,

Panel Sees Over-the-Counter Cough Medicines as Useless  Jan 11, 2006
...coughs. Newer brand name OTC antihistamines, however, such as Zyrtec and Claritin for example, do not help coughs experts say. Even ... - Newsinferno.com,

DemiDose(TM) Pill Splitter Allays Concern Over Dose Accuracy in ...  Jan 11, 2006
Lipitor - Norvasc - Cialis - Zocor - Levitra - Pravachol Mood Women's Health Antibiotic Allergy Migraine - Zyprexa - Fosamax - Levaquin - Zyrtec - Imitrex Oral ... - PR Newswire (press release),

City Councilman resigns  Jan 12, 2006
...and July 5. Those drugs included hydrocodone, marijuana, OxyContin, Zyrtec 10, buspirone hydrochloride and ranitidine. He also is ... - Myrtle Beach Sun News,

Lonza Acquires the Bioproducts Manufacturing Division of UCB  Jan 17, 2006
UCB key products are Keppra(R) (antiepileptic), Xyzal(R) and Zyrtec(R) (antiallergics), Nootropil(R) (cerebral function regulator), Tussionex(R) (antitussive ... - NPIcenter (press release),

Non-prescription cough medicine won't help that cough  Jan 9, 2006
...older-generation antihistamines that work against coughs which include chlorpheniramine, newer, brand-name antihistamines such as Claritin and Zyrtec will not ... - News-Medical.net,

The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.

The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.

Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride.

If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted.